Class of Stock [Axis]
Common shares, no par value
Warrants to purchase common shares, no par value
Warrants to purchase common shares no par value [Member]
Warrants to purchase common shares no par value [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Warrant [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Legal Entity [Axis]
BriaPro Therapeutics Corp, [Member]
Lender Name [Axis]
Bria Cell Therapeutics [Member]
Ownership [Axis]
Investment, Name [Axis]
BC Therapeutics Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Share Purchase Agreement [Member]
Award Type [Axis]
Two Options [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
June 2027 [Member]
Business Combination [Axis]
Amalgamation Agreement [Member]
Long-Lived Asset, Class [Axis]
Office and Lab Space [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Asset Class [Axis]
Cash and Cash Equivalents [Member]
Fair Value, Inputs, Level 2 [Member]
Short-Term Investments [Member]
Liability Class [Axis]
Warrants Liability [Member]
Sale of Stock [Axis]
January 2026 Offering [Member]
Prefunded Warrant [Member]
Class of Warrant or Right [Axis]
Placement Agent Warrants [Member]
Measurement Input Type [Axis]
Measurement Input, Share Price [Member]
Measurement Input, Exercise Price [Member]
Measurement Input, Expected Term [Member]
Measurement Input, Annualized Volatility [Member]
Measurement Input, Expected Dividend Rate [Member]
Measurement Input, Risk Free Interest Rate [Member]
Share Purchase Warrants [Member]
Compensation Warrants [Member]
Warrant One [Member]
Warrant Two [Member]
Warrant Three [Member]
Warrant Four [Member]
Warrant Five [Member]
Warrant Six [Member]
Warrant Seven [Member]
Warrant Eight [Member]
Financial Instrument [Axis]
Bria Pro Warrant [Member]
Plan Name [Axis]
Stock Option Plan [Member]
BriaPro Options [Member]
Related and Nonrelated Parties [Axis]
Exercise Price Range [Axis]
Exercise Price 5.59 [Member]
Exercise Price 12.50 [Member]
Exercise Price 60.00 [Member]
Exercise Price 904.50 [Member]
Exercise Price 1074.00 [Member]
Exercise Price 907.97 [Member]
Exercise Price 706.50 [Member]
Exercise Price 1126.50 [Member]
Exercise Price 1270.50 [Member]
Exercise Price 1074.83 [Member]
Exercise Price 0.0933 [Member]
Exercise Price 0.1108 [Member]
Exercise Price 0.0984 [Member]
Exercise Price 0.0729 [Member]
Exercise Price 0.1162 [Member]
Exercise Price 0.1310 [Member]
Exercise Price 0.1165 [Member]
Restricted Stock Units (RSUs) [Member]
Title and Position [Axis]
Director [Member]
Performance Shares [Member]
Officer [Member]
Chief Financial Officer [Member]
Consolidated Entities [Axis]
National Cancer Institute [Member]
June 2026 Offering [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Statement [Table]
Statement [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement of Financial Position [Abstract]
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
Short-term investments
Amounts receivable and prepaid expenses
Total current assets
NON-CURRENT ASSETS:
Equity investment in BC Therapeutics
Intangible assets, net
Property and equipment, net
Long term prepaid expenses
Total non-current assets
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables
Accrued expenses and other payables
Total current liabilities
NON-CURRENT LIABILITIES:
Warrant liability
Total non-current liabilities
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS’ EQUITY:
Share Capital of no par value – Authorized: unlimited at April 30, 2026 and July 31, 2025; Issued and outstanding: 7,250,487 shares at April 30, 2026 and 1,883,906 July 31, 2025, respectively
Share-based payment reserved
Warrant reserve
Accumulated other comprehensive loss
Non-controlling interest
Accumulated deficit
Total shareholders’ equity
Total liabilities and shareholders’ equity
Common stock, no par value
Common stock, shares authorized unlimited
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Operating Expenses:
Research, development, and clinical trial expenses, net
General and administrative expenses
Total operating expenses
Operating loss
Financial (income) expenses, net
Change in fair value of the warrant liability
Unrealized gain on investment
Share of loss on equity investment
Net loss for the period
Net loss attributable to non-controlling interest
Net loss and Comprehensive loss for the period attributable to BriaCell
Net loss per share attributable to BriaCell - basic
Net loss per share attributable to BriaCell - diluted
Weighted average number of shares used in computing net basic earnings per share of common stock
Weighted average number of shares used in computing net diluted earnings per share of common stock
Balance
Balance, shares
Issuance of Options
Change in ownership of BriaPro
Net loss for the period
Exercise of prefunded warrants
Exercise of prefunded warrants, shares
Issuance of units
Issuance of units, shares
Exercise of broker warrants
Exercise of broker warrants, shares
Balance
Balance, shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization
Financial income, net
Depreciation
Share-based compensation
Share of loss on equity investment
Change in fair value of warrants
Unrealized gain on investment
Changes in working capital:
Increase (decrease) in amounts receivable and prepaid expenses
Decrease in accounts payable
Increase in accrued expenses and other payables
Total cash flow from operating activities
Cash flows from Investing activities
Purchase of equipment
Purchase of short-term investments
Proceeds from short-term investments
Equity investment in BC Therapeutics
Total cash flow from investing activities
Cash flows from financing activities
Proceeds from exercise of warrants
Proceeds from the issuance of shares, net of issuance costs
Total cash flow from financing activities
Increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of the period
Cash and cash equivalents at end of the period
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL AND GOING CONCERN
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES
Investments, All Other Investments [Abstract]
INVESTMENT IN BC THERAPEUTICS INC.
Commitments and Contingencies Disclosure [Abstract]
CONTINGENT LIABILITIES AND COMMITMENTS
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS
Equity [Abstract]
SHAREHOLDERS’ EQUITY
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION
Financial Income Net
FINANCIAL INCOME, NET
Research and Development [Abstract]
RESEARCH, DEVELOPMENT, AND CLINICAL TRIAL EXPENSES, NET
Subsequent Events [Abstract]
SUBSEQUENT EVENT
Use of estimates
Prepaid expenses
The useful life of property and equipment
Investment equity method
Segment reporting
Share-based compensation
Recently issued and adopted accounting standards
SCHEDULE OF CHANGES IN INVESTMENT
SCHEDULE OF ASSETS AND LIABILITIES OF BC THERAPEUTICS
SCHEDULE OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE ON A RECURRING BASIS
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
SUMMARY OF CHANGES IN WARRANTS
SCHEDULE OF WARRANTS OUTSTANDING
SCHEDULE OF CHANGE IN FAIR VALUE OF WARRANTS
SCHEDULE OF VALUATION OF NON PUBLIC OFFERING BROKER WARRANTS
SCHEDULE OF BRIA PRO WARRANTS
Defined Benefit Plan [Table]
Defined Benefit Plan Disclosure [Line Items]
SUMMARY OF NUMBER OF OPTIONS GRANTED
SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS
SCHEDULE OF RESTRICTED STOCK UNITS GRANTED
SCHEDULE OF BRIAPRO RESTRICTED STOCK UNITS GRANTED
SCHEDULE OF PERFORMANCE SHARE UNITS GRANTED
SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES
SCHEDULE OF FINANCIAL INCOME, NET
OrganizationConsolidationAndPresentationOfFinancialStatementsTable [Table]
LineItemsOrganizationConsolidationAndPresentationOfFinancialStatements [Line Items]
Accumulated deficit
Cash flows from operating activities
Gross proceeds from equity
Royalties percentage
Fund for Research and development
Stock Issued During Period, Shares, Other
Subsidiary, Ownership Percentage, Parent
AccountingPoliciesTable [Table]
AccountingPoliciesLineItems [Line Items]
Investment equity method percentage
Number of reportable segment
Restructuring Cost [Table]
Restructuring Cost and Reserve [Line Items]
Beginning balance
Funding
Share of losses
BC Therapeutics Option
Change in fair value during the period
Ending balance
InvestmentsAllOtherInvestmentsTable [Table]
InvestmentsAllOtherInvestmentsLineItems [Line Items]
Current assets: Cash
Net assets
Initial loan
Share price
Ownership percentage
Payments to Acquire Investments
Fair value of option
Exercise price
Dividend yield
Risk free interest rate
Volatility
Expiry date
Options exercised, value
Options exercised
Number of shares issued
Equity interest percentage
Available for purchase shares
Exercise price
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Warrants amount
Warrants exercisable
Warrants shares
Operating lease payments
Fair Value, off-Balance-Sheet Risk [Table]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total assets measured at fair value
Total liabilities measured at fair value
Interest rate on investment percentage
Number of warrants outstanding, beginning balance
Weighted average exercise price, beginning balance
Number of warrants outstanding, expired
Weighted average exercise price, expired
Number of warrants outstanding, granted
Weighted average exercise price, granted
Number of warrants outstanding, ending balance
Weighted average exercise price, ending balance
Weighted average exercise price, expired
Number of warrants outstanding
Exercise price
Number of warrants exercisable
Expiry date
Warrant liability, beginning balance
Change in fair value during the period
Warrant liability, ending balance
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Exercise price
Expected life
Risk free rate
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected life (years)
Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized
Reverse stock split
Sale of stock, number of shares issued
Proceeds from Issuance or Sale of Equity
Share Price
Warrants term
Nominal exercise price per share
Other than nominal exercise price per share
Proceeds from Issuance of Private Placement
Warrant issued
Cashless exercise
Warrants issued
Gross roceeds from issuance of warrants
Warrants and rights outstanding, measurement input
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, beginning balance
Weighted average exercise price, beginning balance
Weighted average remaining contractual term (in years)
Aggregate intrinsic value, beginning balance
Number of options, granted
Weighted average exercise price, granted
Weighted average remaining contractual term (in years), granted
Aggregate intrinsic value, granted
Number of options, expired
Weighted average exercise price, expired
Number of options, ending balance
Weighted average exercise price, ending balance
Aggregate intrinsic value, ending balance
Number of options, exercisable
Weighted average exercise price, exercisable
Weighted average remaining contractual term (in years), exercisable
Aggregate intrinsic value, exercisable
Number of options granted
Number of options issued
Expected volatility
Expected term
Share-Based Payment Arrangement, Option, Exercise Price Range [Table]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price
Options outstanding
Weighted average remaining contractual term (years), options, outstanding
Options exercisable
Weighted average remaining contractual term (years), options, exercisable
Expiry date
Number of RSU's outstanding, beginning balance
Aggregate intrinsic value, beginning balance
Number of RSU's outstanding, granted
Aggregate intrinsic value, granted
Number of RSU's outstanding, ending balance
Aggregate intrinsic value, ending balance
RSU's, granted
Number of options granted
Grant-date fair value
Number of PSU's outstanding, granted
Grant date fair value
Granted shares
Number of PSU's vested
Research, development, and clinical trial expenses
General and administrative expenses
Total share-based compensation
Acquiring percentage of issued and outstanding of common stock
Unrecognized costs
Options issued and outstanding
Schedule Of Financial Income Net
Interest income
Interest expense
Foreign exchange gain (loss)
Financial income, net
ResearchAndDevelopmentTable [Table]
ResearchAndDevelopmentLineItems [Line Items]
Grant received from NCI
Additional grants receivable
Subsequent Event [Table]
Subsequent Event [Line Items]
Purchase and sale of common shares
Warrant issued
Warrants to purchase common shares, no par value
Common shares, no par value
Warrants Liability [Member]
Interest rate on investment percentage.
Placement Agent Warrants [Member]
Measurement Input, Annualized Volatility [Member]
Share Purchase Warrants [Member]
Sharebased compensation arrangement by sharebased payment award nonoption equity instruments outstanding weighted average exercise price.
Sharebased compensation arrangement by sharebased payment award nonoption equity instruments weighted average exercise price expired.
Sharebased compensation arrangement by sharebased payment award nonoption equity instruments weighted average exercise price granted.
Warrant One [Member]
Warrant Two [Member]
Warrant Three [Member]
Warrant Four [Member]
Warrant Five [Member]
Warrant Six [Member]
Warrant Seven [Member]
Warrant Eight [Member]
Compensation Warrants [Member]
Schedule Of Changes In Fair Value Of Warrants [Table Text Block]
Schedule Of Non Public Warranty [Table Text Block]
Schedule Of Bria Pro Warranty [Table Text Block]
Bria Pro Warrant [Member]
Warrants to Purchase Common Shares No Par Value One [Member]
Warrants to Purchase Common Shares No Par Value Two [Member]
Accounts receivable and prepaid expenses current.
Share-based payment reserve.
Warrant reserve.
Acquiring percentage of issued and outstanding of common stock.
Stock Option Plan [Member]
Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual granted.
Share based compensation arrangement by share based payment award options grants in period granted intrinsic value.
Sharebased compensation arrangement by sharebased payment award fair value assumptions expected term
Stock issued during period value exercise of prefunded warrants.
Stock issued during period shares exercise of prefunded warrants.
Exercise Price 12.50 [Member]
Exercise Price 60.00 [Member]
Exercise Price 904.50 [Member]
Exercise Price 1074.00 [Member]
Exercise Price 5.59 [Member]
Exercise Price 907.97 [Member]
Exercise Price 706.50 [Member]
Exercise Price 1270.50 [Member]
Exercise Price 1126.50 [Member]
Exercise Price 1074.83 [Member]
Stock issued during period value exercise of broker warrants.
Stock issued during period shares exercise of broker warrants.
Increase decrease in amounts receivable and prepaid expenses
BriaPro Options [Member]
Exercise Price Zero Point Zero Nine Three Three [Member]
Exercise Price Zero Point One One Zero Eight [Member]
Exercise Price Zero Point Zero Nine Eight Four [Member]
Exercise Price Zero Point Zero Seven Two Nine [Member]
Exercise Price Zero Point One One Six Two [Member]
Exercise Price Zero Point One Three One Zero [Member]
Exercise Price Zero Point One One Six Five [Member]
Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value outstanding granted.
BriaPro Therapeutics Corp, [Member]
Prepaid Expenses [Policy Text Block]
BC Therapeutics Inc [Member]
Schedule Of Share Based Compensation Expenses [TableTextBlock]
National Cancer Institute [Member]
Share Purchase Agreement [Member]
Two Options [Member]
Amalgamation Agreement [Member]
Office and Lab Space [Member]
General and administrative expenses including share-based compensation.
Research, development, and clinical trial expenses including share-based compensation.
Royalties percentage
Bria Cell Therapeutics [Member]
Financial income expenses net
January 2026 Offering [Member]
Financial Income Expenses Disclosure [Text Block]
Schedule of Financial Income [Table Text Block]
June 2027 [Member]
Gain loss on derivative instruments not designated as hedging instruments.
Prefunded Warrant [Member]
Nominal exercise price per share
Other than nominal exercise price per share
June 2026 Offering [Member]
Warrants to purchase common shares no par value [Member] [Default Label]
Assets, Current
Assets, Noncurrent
Assets
Liabilities, Current
Liabilities, Noncurrent
Equity, Including Portion Attributable to Noncontrolling Interest
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Shares, Outstanding
FinancialIncomeExpensesNet
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Short-Term Investments
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Commitments and Contingencies Disclosure [Text Block]
Share-Based Payment Arrangement [Policy Text Block]
Equity Method Investments
Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations
Class of Warrant or Right, Exercise Price of Warrants or Rights
Warrants and Rights Outstanding, Maturity Date
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingGranted
GeneralAndAdministrativeExpensesIncludingShareBasedCompensation
Employee Benefit and Share-Based Payment Arrangement, Noncash
Interest Expense, Nonoperating